Study comparing secukinumab (Cosentyx) versus adalimumab (Humira) in the treatment of active psoriatic arthritis

This is a 52-week trial comparing adalimumab versus secukinumab for the treatment of active psoriatic arthritis. Both treatments are FDA approved for psoriatic arthritis; however this study seeks to determine which drug is superior.

Subjects must be at least 18 years old and must have a diagnosis of psoriatic arthritis and at least one psoriatic plaque on their skin. Subjects must not have ever taken any biologic drugs for psoriatic arthritis such as Humira.

Subjects may receive up to $1490 for participation in this study. All medication and study visits are performed at no cost to the participant.